Chrysalis BioTherapeutics Overview
- Year Founded
-
1995
- Status
-
Private
- Employees
-
5
- Latest Deal Type
-
Series A
- (Upcoming)
- Investors
-
2
Chrysalis BioTherapeutics General Information
Description
Developer of regenerative anti-inflammatory drugs designed to repair damaged tissues and reduce inflammatory responses associated with severe medical conditions. The company offers stem cell and endothelial progenitor cell-activating therapies for tissue regeneration, radiation injury mitigation, and inflammation management, enabling healthcare providers and patients to support recovery from acute lung injury, the effects of cancer treatment, and radiation exposure.
Contact Information
Website
www.chrysbio.comCorporate Office
- 1700 Strand Street
- Suite 2.302
- Galveston, TX 77550
- United States
Corporate Office
- 1700 Strand Street
- Suite 2.302
- Galveston, TX 77550
- United States
Chrysalis BioTherapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Later Stage VC (Series A) | Upcoming | Clinical Trials - General | ||||
| 5. Seed Round | 22-Mar-2024 | Completed | Clinical Trials - General | |||
| 4. Grant | 10-Jun-2020 | Completed | Clinical Trials - General | |||
| 3. Grant | 05-Jun-2020 | Completed | Clinical Trials - General | |||
| 2. Grant | 09-May-2016 | $3M | Completed | Clinical Trials - General | ||
| 1. Merger/Acquisition | 05-Aug-2004 | $34.5M | Completed | Clinical Trials - General |
Chrysalis BioTherapeutics Patents
Chrysalis BioTherapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260165965-A1 | Stabilized tp508 formulations | Pending | 17-Dec-2024 | ||
| WO-2024211447-A1 | Tp508 mrnas | Inactive | 03-Apr-2023 | ||
| CA-3179798-A1 | Tp508 acute therapy for patients with respiratory virus infection | Pending | 07-Apr-2020 | ||
| EP-4132948-A1 | Tp508 acute therapy for patients with respiratory virus infection | Inactive | 07-Apr-2020 | ||
| EP-4132948-A4 | Tp508 acute therapy for patients with respiratory virus infection | Inactive | 07-Apr-2020 | C12Y304/21005 |
Chrysalis BioTherapeutics Signals
Chrysalis BioTherapeutics Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| National Institutes of Health | Government | |||
| National Institute Of Allergy and Infectious Diseases | Government |
Chrysalis BioTherapeutics FAQs
-
When was Chrysalis BioTherapeutics founded?
Chrysalis BioTherapeutics was founded in 1995.
-
Where is Chrysalis BioTherapeutics headquartered?
Chrysalis BioTherapeutics is headquartered in Galveston, TX.
-
What is the size of Chrysalis BioTherapeutics?
Chrysalis BioTherapeutics has 5 total employees.
-
What industry is Chrysalis BioTherapeutics in?
Chrysalis BioTherapeutics’s primary industry is Drug Discovery.
-
Is Chrysalis BioTherapeutics a private or public company?
Chrysalis BioTherapeutics is a Private company.
-
What is Chrysalis BioTherapeutics’s current revenue?
The current revenue for Chrysalis BioTherapeutics is .
-
How much funding has Chrysalis BioTherapeutics raised over time?
Chrysalis BioTherapeutics has raised $515K.
-
Who are Chrysalis BioTherapeutics’s investors?
National Institutes of Health and National Institute Of Allergy and Infectious Diseases have invested in Chrysalis BioTherapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process